Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies546
  • 7D5.0%
  • 3M5.3%
  • 1Y40.4%
  • YTDn/a

The Biotech industry is up 5.0% in the last week, with Gilead Sciences up 4.1%. This takes the industry's 12 month performance to a gain of 40%. Looking forward, earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026US$1.3tUS$166.1b-US$11,838,749,747.8416x-108.9x7.8x
Tue, 03 Mar 2026US$1.4tUS$169.4b-US$12,634,834,488.1021.8x-106.9x8x
Thu, 29 Jan 2026US$1.3tUS$163.6b-US$15,062,594,674.9119.8x-84.8x7.8x
Sat, 27 Dec 2025US$1.3tUS$163.6b-US$15,776,614,106.3522x-79.3x7.6x
Mon, 24 Nov 2025US$1.2tUS$163.8b-US$16,230,751,145.9818.2x-74.3x7.4x
Wed, 22 Oct 2025US$1.2tUS$163.4b-US$18,378,998,645.5816.2x-64.4x7.2x
Fri, 19 Sep 2025US$1.1tUS$163.5b-US$18,381,106,242.3916.9x-58.1x6.5x
Sun, 17 Aug 2025US$1.1tUS$163.6b-US$18,739,718,949.9515.6x-57.4x6.6x
Tue, 15 Jul 2025US$974.2bUS$155.8b-US$23,412,837,702.4818x-41.6x6.3x
Thu, 12 Jun 2025US$959.4bUS$155.9b-US$23,944,577,514.8416.9x-40.1x6.2x
Sat, 10 May 2025US$879.4bUS$154.9b-US$24,542,496,165.1116.7x-35.8x5.7x
Mon, 07 Apr 2025US$735.9bUS$118.6b-US$37,018,260,571.7320.1x-19.9x6.2x
Wed, 05 Mar 2025US$831.7bUS$119.0b-US$37,123,415,733.9016.4x-22.4x7x
Fri, 31 Jan 2025US$990.2bUS$149.5b-US$26,311,030,486.4317.4x-37.6x6.6x
Sun, 29 Dec 2024US$977.8bUS$149.9b-US$26,372,711,577.3016.2x-37.1x6.5x
Tue, 26 Nov 2024US$1.0tUS$150.0b-US$26,579,608,946.2716.4x-38.2x6.8x
Thu, 24 Oct 2024US$897.0bUS$113.1b-US$36,020,164,121.5521x-24.9x7.9x
Sat, 21 Sep 2024US$927.5bUS$113.2b-US$35,987,032,000.3121.9x-25.8x8.2x
Mon, 19 Aug 2024US$883.2bUS$113.2b-US$35,819,260,655.8322.3x-24.7x7.8x
Wed, 17 Jul 2024US$1.2tUS$164.5b-US$28,050,454,935.0729.4x-42.6x7.3x
Fri, 14 Jun 2024US$1.2tUS$164.5b-US$28,081,541,373.9827.8x-41.3x7.1x
Sun, 12 May 2024US$1.1tUS$164.6b-US$26,967,551,943.9823.3x-41.2x6.7x
Tue, 09 Apr 2024US$1.1tUS$164.4b-US$23,377,181,270.8821x-48.3x6.9x
Thu, 07 Mar 2024US$1.2tUS$167.9b-US$21,278,119,441.9516x-55.9x7.1x
Sat, 03 Feb 2024US$1.4tUS$203.9b-US$24,418,168,728.0019.2x-58.9x7.1x
Mon, 01 Jan 2024US$1.4tUS$204.9b-US$22,199,078,413.0019.8x-62.6x6.8x
Wed, 29 Nov 2023US$1.2tUS$204.8b-US$22,005,071,481.0017.8x-55.6x6x
Fri, 27 Oct 2023US$1.2tUS$207.5b-US$12,993,510,910.0016.8x-93.2x5.8x
Sun, 24 Sep 2023US$1.3tUS$207.5b-US$12,879,333,723.0017.1x-97.9x6.1x
Tue, 22 Aug 2023US$1.3tUS$207.6b-US$12,363,308,148.0017.5x-102.3x6.1x
Thu, 20 Jul 2023US$1.1tUS$186.6b-US$15,972,272,220.0012.8x-71.5x6.1x
Sat, 17 Jun 2023US$1.2tUS$186.3b-US$16,045,332,946.0012.1x-72.3x6.2x
Mon, 15 May 2023US$1.2tUS$191.7b-US$12,222,188,637.0013.8x-94.5x6x
Wed, 12 Apr 2023US$1.2tUS$198.3b-US$3,303,389,351.0013.9x-351.9x5.9x
Price to Earnings Ratio

-351.9x


Total Market Cap: US$1.2tTotal Earnings: -US$3,303,389,351.00Total Revenue: US$198.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -62.4x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechnology industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 7.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
  • Revenues have also declined 5.7% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Comparison

How does U.S. Biotech compare with similar industries?

US Market3.46%
Healthcare3.50%
Biotech5.00%
Biotech5.00%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GILD Gilead SciencesUS$139.714.1%
+US$6.8b		30.3%PE20.4x
INSM InsmedUS$162.4311.8%
+US$3.7b		134.8%PS57.8x
NTRA NateraUS$207.9813.9%
+US$3.6b		55.4%PS12.8x
ONC BeOne MedicinesUS$310.799.8%
+US$3.1b		30.3%PE120.1x
APLS Apellis PharmaceuticalsUS$40.41138.1%
+US$3.0b		102.4%PE230.8x

Latest News

REGN
US$761.85
Regeneron Pharmaceuticals
7D
3.3%
1Y
32.9%
GILD
US$139.71
Gilead Sciences
7D
4.1%
1Y
30.3%

GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength

Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.
CNTA
US$39.69
Centessa Pharmaceuticals
7D
38.3%
1Y
239.8%
INSM
US$162.43
Insmed
7D
11.8%
1Y
134.8%
NTRA
US$207.98
Natera
7D
13.9%
1Y
55.4%
SMMT
US$19.38
Summit Therapeutics
7D
16.9%
1Y
11.6%

Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity

Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing ivonescimab for the treatment of multiple solid tumor cancers. What are the underlying business or industry changes driving this perspective?
ONC
US$310.79
BeOne Medicines
7D
9.8%
1Y
30.3%

ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside

BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.
COGT
US$35.21
Cogent Biosciences
7D
-2.5%
1Y
638.2%
ORIC
US$8.89
ORIC Pharmaceuticals
7D
-26.3%
1Y
82.2%
PEPG
US$1.73
PepGen
7D
-61.7%
1Y
58.0%
VRDN
US$18.84
Viridian Therapeutics
7D
-31.2%
1Y
57.1%
ABBV
US$208.84
AbbVie
7D
-0.3%
1Y
11.7%
APLS
US$40.41
Apellis Pharmaceuticals
7D
138.1%
1Y
102.4%
BIIB
US$177.34
Biogen
7D
-3.5%
1Y
44.2%
AMGN
US$347.94
Amgen
7D
-0.2%
1Y
18.2%

AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.
MRNA
US$49.20
Moderna
7D
-0.7%
1Y
95.9%

MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside

Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.